Significant progress highlights the role of immune and inflammatory markers in predicting cancer and cardiovascular outcomes. A novel immune cell model utilizing multiplex immunofluorescence forecasts ovarian cancer prognosis, emphasizing immunological involvement in tumor biology. Additionally, the systemic immune-inflammation index (SII) correlates with poor prognosis in heart failure patients with preserved ejection fraction, offering prognostic value. Further research links the LncRNA938/TAF9/TTK axis with hepatoblastoma progression, suggesting new molecular targets for therapy.